DexComvs.Eli Lilly
DXCM vs LLY · both in Diabetes & metabolic disease, part of the Medicine, pharma & life science value chain: Treatment and monitoring of diabetes and metabolic disease — from insulin to glucose monitoring.
Eli Lilly is about 39× larger than DexCom by market cap; DexCom trades at the lower P/E (31.1 vs 44.3).
Side by side
| DXCM | LLY | |
|---|---|---|
| Market cap | $28.9B | $1.1T |
| Price | $74.96 | $1,188.58 |
| Today | +2.7% | −2.3% |
| Return YTD | +12.9% | +10.6% |
| Return 1Y | −12.3% | +50.3% |
| P/E | 31.1 | 44.3 |
| P/S | 6.0 | 15.5 |
| P/B | 9.8 | 35.9 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
DexComDXCM
American medtech company focused on continuous glucose monitoring (CGM) for people with diabetes.
Full DXCM profile →Eli LillyLLY
American pharmaceutical group with one of the industry's strongest pipelines — GLP-1 products Mounjaro and Zepbound, alongside treatments in diabetes, oncology and neurology.
Full LLY profile →More comparisons in Diabetes & metabolic disease
See where DXCM and LLY sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →